ClinTB Analytics: LC-MS/MS Quantitation of Antibiotics and Drugs
With financial support from the DZIF-Site Hamburg-Lübeck-Borstel-Riems we installed in Juli 2021 an additional LC-MS/MS platform. As part of our mandate, we now offer our expertise for preclinical studies as wells as descriptive studies. At the moment we are validating the newly installed instrument (XEVO). The platform is managed by Dr. Franziska Marwitz (m.n. Waldow) and the bioanalytical chemistry team.
This platform consists of a 1100 LC-systems (Agilent) and a triple quadrupole mass specrometers (XEVO-TQ, Premier XE, Waters) to perform MRM (Multi Reaction Monitoring) analyses in complex sample matrices. The method was developed to cover all importnat antibiotics for treating tuberculosis. However, we also offer to customize the analytical strategy for novel compounds. A short overview on platform is shown here.
You can contact us via
The platform and method was applied for the following studies:
- Interleukin-13 overexpressing mice represent an advanced pre-clinical model for detecting the distribution of anti-mycobacterial drugs within centrally necrotizing granulomas.
Walter K, Kokesch-Himmelreich J, Treu A, Waldow F, Hillemann D, Jakobs N, Lemm AK, Schwudke D, Römpp A, Hölscher C.
Antimicrob Agents Chemother. 2021. doi: 10.1128/AAC.01588-21. PMID: 34871095
- Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery.
Huck BC et all. ... Waldow F, Schwudke D, ... Loretz B, Lehr CM.
Advanced Healthcare Materials 2022. doi: 10.1002/adhm.202102117 - Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects.